Dalfopristin and quinupristin and Pexidartinib
Determining the interaction of Dalfopristin and quinupristin and Pexidartinib and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration of pexidartinib with moderate CYP450 3A4 inhibitors may increase the plasma concentrations and the risk of adverse effects of pexidartinib, including potentially fatal hepatotoxicity. The proposed mechanism is inhibition of CYP450 3A4, the primary isoenzyme responsible for the metabolic clearance of pexidartinib. Concomitant administration of itraconazole, a strong CYP450 3A4 inhibitor, increased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 48% and 70%, respectively. No data are available regarding the effects that other, less potent CYP450 3A4 inhibitors may have on the pharmacokinetics of pexidartinib. MANAGEMENT: Caution is advised if pexidartinib is used with moderate CYP450 3A4 inhibitors. It is unknown if pexidartinib will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring of pexidartinib should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be monitored for adverse effects. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Professional:MONITOR: Coadministration of pexidartinib with moderate CYP450 3A4 inhibitors may increase the plasma concentrations and the risk of adverse effects of pexidartinib, including potentially fatal hepatotoxicity. The proposed mechanism is inhibition of CYP450 3A4, the primary isoenzyme responsible for the metabolic clearance of pexidartinib. Concomitant administration of itraconazole, a strong CYP450 3A4 inhibitor, increased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 48% and 70%, respectively. No data are available regarding the effects that other, less potent CYP450 3A4 inhibitors may have on the pharmacokinetics of pexidartinib.
MANAGEMENT: Caution is advised if pexidartinib is used with moderate CYP450 3A4 inhibitors. It is unknown if pexidartinib will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring of pexidartinib should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be monitored for adverse effects.
- "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Generic Name: dalfopristin / quinupristin
Brand name: Synercid
Synonyms: Quinupristin and Dalfopristin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dalfopristin and quinupristin-Pexidartinib Hydrochloride
- Dalfopristin and quinupristin-Pfizerpen
- Dalfopristin and quinupristin-Pharaon Tea
- Dalfopristin and quinupristin-Pharmorubicin Pfs
- Dalfopristin and quinupristin-Phazyme
- Dalfopristin and quinupristin-Phazyme Liquid Gas Relief, Maximum Strength
- Pexidartinib-Daliresp
- Pexidartinib-Dallergy
- Pexidartinib-Dallergy (Dexbrompheniramine and Phenylephrine Syrup)
- Pexidartinib-Dallergy (Dexbrompheniramine and Phenylephrine Tablets)
- Pexidartinib-Dallergy Chewable Tablets
- Pexidartinib-Dallergy Drops